Fusions of cytokines and tumor targeting proteins
CA 2484425 A1 · Owner: Molmed Spa · Inventors: Corti, Angelo; Curnis, Flavio
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A conjugate of a cytokine and a tumor targeting moiety (TTM) with the provisos that when cytokine is TNF-.alpha. TNF-.beta. or IFN-.gamma. the TTM is other than a CD13 ligant; when the cytokine is IL-12 the TTM is other than an , antiboy to fibronectin; when the cytokine is TNF the TTM is other than an , antibody to the transferrin receptor; and when the cytokine is TNF IFN-, .gamma. or IL-2 the antibody is other than an antibody to the TAG72 antigen.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 30, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 30, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 30, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.